TCGA-85-8584-01A-11R-2403-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- COMPLEMENT+0.280
- TNFA_SIGNALING_VIA_NFKB+0.280
- XENOBIOTIC_METABOLISM+0.260
- E2F_TARGETS+0.250
- APICAL_SURFACE+0.230
- COAGULATION+0.230
Top 10 suppressed
- PROTEIN_SECRETION-0.330
- OXIDATIVE_PHOSPHORYLATION-0.300
- NOTCH_SIGNALING-0.290
- UV_RESPONSE_DN-0.280
- HEDGEHOG_SIGNALING-0.240
- ADIPOGENESIS-0.180
- ANDROGEN_RESPONSE-0.160
- CHOLESTEROL_HOMEOSTASIS-0.160
- HEME_METABOLISM-0.160
- BILE_ACID_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_GAGRGSSX | ATRT | — | 0.786 |
| 2 | DRR168610 | — | — | 0.779 |
| 3 | MNG539 | — | — | 0.775 |
| 4 | TCGA-21-1070-01A-01R-0692-07 | — | cohortSQ1 | 0.750 |
| 5 | SRR5088821 | — | — | 0.746 |
| 6 | R317 | — | — | 0.740 |
| 7 | 346fe4c0-2ea0-45b4-8863-b0f9e7756ad6 | — | — | 0.737 |
| 8 | 6d7694d5-8582-466f-8072-df47dc10d780 | — | — | 0.734 |
| 9 | SRR810571 | GTEX | — | 0.733 |
| 10 | SRR10900548 | — | — | 0.729 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |